6453-88-9

Basic information

• Product Name: N-(2-bromoethyl)benzenesulfonamide
• CAS NO: 6453-88-9
• Molecular Formula: C₈H₁₀BrNO₂S
• Molecular Weight: 264.1395
• Mol File: 6453-88-9.mol

Chemical Properties

• Boiling Point: 359.3°C at 760 mmHg
• Flash Point: 171.1°C
• Density: 1.556g/cm³
• Vapor Pressure: 2.4E-05mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: N-(2-bromoethyl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-bromoethyl)benzenesulfonamide(6453-88-9)
• EPA Substance Registry System: N-(2-bromoethyl)benzenesulfonamide(6453-88-9)

Safety Data

• Hazardous Substances Data: 6453-88-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-bromoethyl)benzenesulfonamide is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its role as a sulfonamide allows it to contribute to the development of antibacterial agents and treatments for a range of diseases.
Used in Pesticide Industry:
In the pesticide industry, N-(2-bromoethyl)benzenesulfonamide is utilized as an intermediate in the production of pesticides. Its chemical properties make it a valuable component in creating effective pest control solutions.

Upstream product

• 2576-47-8 2-bromoethylamine hydrobromide 
• 98-09-9 benzenesulfonyl chloride 
• 98-10-2 benzenesulfonamide 

Downstream Products

• 141286-78-4 2-[2,6-difluoro-4-({2-[(phenylsulfonyl)amino]ethyl}thio)phenoxy]acetamide 
• 10302-15-5 N-(phenylsulfonyl)aziridine 

Relevant articles and documents

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS

This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently represent CO, SO or SO

Solvent interception, heterocyclization and desilylation upon NBS-induced sulfamidation of trimethyl(vinyl)silane

The reaction of trimethyl(vinyl)silane with sulfonamides in the presence of N-bromosuccinimide was shown to proceed regioselectively in methylene chloride under mild conditions and led to the products of bromosulfamidation in up to 88% yield. The obtained adducts undergo base-promoted dehydrobromination to give 2-trimethylsilyl-N-sulfonyl aziridines in a close to quantitative yield. In the reaction with trifluoromethanesulfonamide in acetonitrile or tetrahydrofuran, the Ritter-type (solvent-interception) products were obtained and converted to 1-triflyl-2-methyl-5-(trimethylsilyl)-2-imidazoline or 4-triflyl-3-(trimethylsilyl)-1,4-oxazocane in almost quantitative yield.

In vivo AMPA receptors in the brain imaging method of primates, program, and screening method

This imaging method of AMPA receptors in the brain of primate organisms involves a step in which a substance which is administered to the primate organism and which selectively bonds to AMPA receptors in the brain of the primate organism and has a radiola

In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase

A structure-based virtual screening of commercial compounds was carried out on the HCV NS3 helicase structure, with the aim to identify novel inhibitors of HCV replication. Among a selection of 13 commercial structures, one compound was found to inhibit the subgenomic HCV replicon in the low micromolar range. Different series of new piperazine-based analogues were designed and synthesised, and among them, several novel structures exhibited antiviral activity in the HCV replicon assay. Some of the new compounds were also found to inhibit HCV NS3 helicase function in?vitro, and one directly bound NS3 with a dissociation constant of 570?±?270?nM.

OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES 2

Compounds of formula (I): wherein A, X, R1, R2, R3, R4, R5, R6 and R8 are as defined in the Specification are useful in the treatment of diseases where enhanced M3 receptor activ